VNDA On Watch, NUVA Q2 Results Miss Estimates, MRTX Awaits FDA Decision…
The following are some of the healthcare companies that reported quarterly financial results and provided a pipeline update on Wednesday. 1. Vanda To Report Bipolar Disorder Trial Results By Year-end Vanda Pharmaceuticals Inc. (VNDA), which reported a 5% decrease in total net product sales in the second quarter of 2022, has a couple of make-or-break events to watch in the […]
Read more